
Reset all filters
01 3Diovan
02 6Diovan Group
03 2Diovan/Co-Diovan
04 2Entresto
05 6Exforge
06 5Exforge Group
Hydrochlorothiazide, Valsartan
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2020 Revenue in Millions : 980
2019 Revenue in Millions : 1,025
Growth (%) : -4
Hydrochlorothiazide, Valsartan
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2020 Revenue in Millions : 1,003
2019 Revenue in Millions : 1,064
Growth (%) : -6
Hydrochlorothiazide, Valsartan
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2020 Revenue in Millions : 2,497
2019 Revenue in Millions : 1,726
Growth (%) : 45
Hydrochlorothiazide, Valsartan
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2021 Revenue in Millions : 773
2020 Revenue in Millions : 1,003
Growth (%) : -23
Hydrochlorothiazide, Valsartan
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2021 Revenue in Millions : 901
2020 Revenue in Millions : 980
Growth (%) : -8
Hydrochlorothiazide, Valsartan
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2022 Revenue in Millions : 652
2021 Revenue in Millions : 773
Growth (%) : -16
Hydrochlorothiazide, Valsartan
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2022 Revenue in Millions : 743
2021 Revenue in Millions : 901
Growth (%) : -18
Hydrochlorothiazide, Valsartan
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2023 Revenue in Millions : 713
2022 Revenue in Millions : 743
Growth (%) : -4
Hydrochlorothiazide, Valsartan
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2023 Revenue in Millions : 613
2022 Revenue in Millions : 652
Growth (%) : -6
Hydrochlorothiazide, Valsartan
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2024 Revenue in Millions : 590
2023 Revenue in Millions : 613
Growth (%) : -4